Drug Monograph

Drug/Drug Class:	**Cuvitru® (human immunoglobulin g) solution for injection /Primary Humoral Immunodeficiency**
Prepared for:	MO HealthNet
Prepared by:	Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Cuvitru® is a 20% protein solution for subcutaneous infusion. It is available in single use vials containing the labeled amount of functionally active IgG. The following presentations are available: 1 g protein per 5 ml, 2 g protein per 10 ml, 4 g protein per 20 ml, and 8 g protein per 40 ml.
Manufacturer:	Baxalta US Inc., Westlake Village, CA 91362
Indications:	Cuvitru® is indicated as replacement therapy for primary humoral immunodeficiency in adult and pediatric patients two years of age and older.
Costs:	$33.93 per ml of Cuvitru®. Maximum Allowable Cost
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.
Status Recommendation:	☐ Prior Authorization (PA) Required ☒ Open Access ☐ Fiscal Edit ☐ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Under Solicitation ☐ Appropriate Indications ☒ No PA Required

Prepared By: Luke Boehmer Pharm.D.
Date: February 16, 2017

© 2017 Conduent Business Services, LLC All Rights Reserved.